TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: GSS (Global Sleep Score)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: CCT change (Central Corneal Thickness change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean proportion of hemoglobin values in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective efficacy to prevent clinical infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean peak plasma level of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic correlation with SCA risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: triclosan concentration in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibacterial efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OGSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent ischemic stroke, myocardial infarction, or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Clinical outcome improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of thyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean vaginal cuff closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgeon rating of ease of cuff closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of analgesics used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times pain expressed outside fixed intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients becoming asymptomatic
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average tear production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: debilitating physical side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of relationship with primary care provider
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to predict presence of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EC50 of propofol for colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting C-peptide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture cases
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of eligible elderly patients receiving aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible elderly patients receiving beta-blockers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of anatomical form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of marginal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) assessment in patients over 65
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: disease-free survival (DFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rate in CRC screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unsedated colonoscopies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: serum transaminase levels on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS value considered useful
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy expenditure (thermogenesis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ≥50% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ≥75% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MMD (Mean Migraine Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD44 gene transcription and methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heavy drinking intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: basophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: tremor severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of recurrence of TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TVA dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total phenylpropanolamine eliminated unchanged
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pseudoephedrine eliminated unchanged
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum urine concentrations of phenylpropanolamine and pseudoephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLMS index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac activation amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deletion of chromosome 16q24 and loss of E-cadherin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Favorable status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clearance of HPV 16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: GFR enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PC20 in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum percentage fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurologic functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Terminal deoxynucleotidyl transferase‐mediated dUTP nick end labeling–positive neuron rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microglia area/anterior horn area ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: re-osseointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: bone remodeling activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall response time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error rate decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma morphine concentration versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miosis peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum calculated effect-site morphine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of >or=4 mm probing depths (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative TIMI flow grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adhesion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ovarian weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of emergency department or urgent in-office visits for heart failure, arrhythmias, or ICD-related events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total healthcare visits for heart failure, arrhythmias, or ICD-related events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of life change (Minnesota Living With Heart Failure Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: whole breast-milk HIV-1 RNA loads <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 DNA loads <10 copies/10(6) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duodenal injury assessed by Lanza score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: scar size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inferior wall systolic thickening improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mid-distal PUL improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to proliferative diabetic retinopathy (PDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to severe nonproliferative retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain and local tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bone ALP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subjective quality sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Tinetti Balance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: improvement in neurologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: substance misuse outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological effects compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum clusterin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visceral fat area (VFA) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: duration of closed suction drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of fluid collected by closed suction drains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mobility decline risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per ocular HSV episode averted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma vitamin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MADRS‐S depression scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS depression scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen saturation dropping below 95%
Endpoint domain: Adverse events/effects
Primary endpoint: Phoneme recognition in AV mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance and distensibility in CCA and FA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: peak Vo2 test-retest reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased levels of IGF‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased postprandial IGFBP‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in age‐corrected IGF‐1 SD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Daily exercise adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ease of exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of delirium
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain at normal activity 24h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at quick movement/coughing 24h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of sick leave
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Up-regulation of serum cytokines/chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of proliferating NK and activated total CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppression of HBV replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in signs and symptoms of knee OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Renal (edema) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Increased allergen specific IgA levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in the magnitude of the late‐phase cutaneous reaction to bee venom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in the proliferation of venom‐stimulated PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction in the production of IL‐13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically relevant toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: severe adverse pregnancy/neonatal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation of BT (Behavioral Therapy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of MAT (Medication-Assisted Treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sero-response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibiotic prescriptions per 1000 patients per GP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma/COPD prescriptions per 1000 patients per GP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-of-study intact PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coronary artery calcium score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum liver tests improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow joint activity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in biceps brachii IEMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS symptom intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of significant lymphoceles over 1500 mm(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eotaxin expression in nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from TLR or restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage in remission (DAS28 <2.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in positive surgical site cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Variability in blood tacrolimus concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drug exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: initial urine volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: self-reported nausea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the vigilance task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSM compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of missed pill instructions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of CCK‐4‐induced panic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and intensity of panic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular response to CCK‐4 challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Employability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cumulative probability of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of anti-VSACSA IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: postoperative increase of exophthalmos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude and intentions toward exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total score of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' overall idea about the drugs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transmission of LIV signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NO content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAPS-5 total symptom severity score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher rates of PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of NHDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable sinus rhythm off antiarrhythmic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective discomfort evaluation of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Final treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of inquiry about incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Grade III/IV thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative healing rates after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes